This study investigates non-small cell lung cancer (NSCLC) with c-Met EXON 14 skip mutations and c-Met dysregulation in advanced solid tumors. The purpose of this study is to explore how the investigational medication works with these specific genetic changes in cancer.
The study evaluates the safety, effectiveness, and tolerability of the investigational medication. Researchers are looking at various types of tumors to understand how the medication affects them.
- Who can participate: Adults aged 18 and older with specific genetic markers related to c-Met in their cancer may be eligible. Participants must have a measurable lesion and meet specific health criteria.
- Study details: Participants will take the investigational medication, which may be combined with other treatments. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand